Interferon Alfa With or Without Isotretinoin in Treating Patients With Metastatic Kidney Cancer
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
RATIONALE: Interferon alfa may interfere with the growth of the cancer cells and slow the
growth of kidney cancer. Isotretinoin may help kidney cancer cells develop into normal cells.
It is not yet known whether interferon alfa plus isotretinoin is more effective than
interferon alfa alone for kidney cancer.
PURPOSE: Randomized phase III trial to compare the effectiveness of interferon alfa with or
without isotretinoin in treating patients who have metastatic kidney cancer.
Phase:
Phase 3
Details
Lead Sponsor:
European Organisation for Research and Treatment of Cancer - EORTC